Neutralising and binding anti-interferon-β-1b (IFN-β-1b) antibodies during IFN-β-1b treatment of multiple sclerosis

Multiple Sclerosis

Volumn 3, Issue 3, 1997, Pages 184-190

  Kivisakk P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; B cells; Interferon ; Multiple sclerosis; Treatment

Indexed keywords

BETA1 INTERFERON; INTERFERON ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS;

EID: 0030770887     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859700300303     Document Type: Article

References (3)

1. The IFNB Multiple Sclerosis Study Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomised controlled trial. Neurology 45: 1277-1285.
2. The IFNB Multiple Sclerosis Study Group. (1996) Neutralising antibodies during treatment of multiple sclerosis with Interferon beta-1b: Experience during the first three years. Neurology 47: 889-894.
3. von Wussow P et al. (1987) Clinical significance of anti-IFN-α antibody titres during interferon therapy. Lancet 12: 635-630.